Evidence map›Paper›PMID 24509297›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2014

Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1.

Anthony J Bleyer, Stanislav Kmoch, Corinne Antignac, Vicki Robins, Kendrah Kidd, John R Kelsoe, Gerald Hladik, Philip Klemmer, Stephen J Knohl, Steven J Scheinman and 24 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03747523 (Study of the Effect of Ergocalciferol on Plasma and Urinary Mucin-1 Levels in Healthy Individuals and Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03747523 early_phase1completednot on this mapstarted 2019, after this paper: background citation

Study of the Effect of Ergocalciferol on Plasma and Urinary Mucin-1 Levels in Healthy Individuals and Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations (ADTKD-MUC1)

TypeinterventionalSponsorWake Forest University Health SciencesRan2019 to 2020Enrolled44ConditionsErgocalciferolArmsErgocalciferol
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Cross-phenotype association analysis of gastric cancer: in-silico functional annotation based on the disease-gene network.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Long-Read Sequencing of thebioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. Article
  11. Clinical kidney journal · 2025
    Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  18. Article
  19. Genetic Susceptibility to Chronic Kidney Disease: Links, Risks and Management.International journal of nephrology and renovascular disease · 2023
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 1 institution in 1 country.

Anthony J BleyerDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Stanislav Kmoch
Corinne Antignac
Vicki Robins
Kendrah Kidd
John R Kelsoe
Gerald Hladik
Philip Klemmer
Stephen J Knohl
Steven J Scheinman
Nam Vo
Ann Santi
Alese Harris
Omar Canaday
Nelson Weller
Peter J Hulick
Kristen Vogel
Frederick F Rahbari-Oskoui
Jennifer Tuazon
Constantinos Deltas
Douglas Somers
Andre Megarbane
Paul L Kimmel
C John Sperati
Avi Orr-Urtreger
Shay Ben-Shachar
David A Waugh
Stella McGinn
Anthony J Bleyer
Katerina Hodanová
Petr Vylet'al
Martina Živná
Thomas C Hart
P Suzanne Hart
Wake Forest University · US

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe genetic cause of medullary cystic kidney disease type 1 was recently identified as a cytosine insertion in the variable number of tandem repeat region of MUC1 encoding mucoprotein-1 (MUC1), a protein that is present in skin, breast, and lung tissue, the gastrointestinal tract, and the distal tubules of the kidney. The purpose of this investigation was to analyze the clinical characteristics of families and individuals with this mutation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Families with autosomal dominant interstitial kidney disease were referred for genetic analysis over a 14-year period. Families without UMOD or REN mutations prospectively underwent genotyping for the presence of the MUC1 mutation. Clinical characteristics were retrospectively evaluated in individuals with the MUC1 mutation and historically affected individuals (persons who were both related to genetically affected individuals in such a way that ensured that they could be genetically affected and had a history of CKD stage IV or kidney failure resulting in death, dialysis, or transplantation).

resultsTwenty-four families were identified with the MUC1 mutation. Of 186 family members undergoing MUC1 mutational analysis, the mutation was identified in 95 individuals, 91 individuals did not have the mutation, and111 individuals were identified as historically affected. Individuals with the MUC1 mutation suffered from chronic kidney failure with a widely variable age of onset of end stage kidney disease ranging from 16 to >80 years. Urinalyses revealed minimal protein and no blood. Ultrasounds of 35 individuals showed no medullary cysts. There were no clinical manifestations of the MUC1 mutation detected in the breasts, skin, respiratory system, or gastrointestinal tract.

conclusionMUC1 mutation results in progressive chronic kidney failure with a bland urinary sediment. The age of onset of end stage kidney disease is highly variable, suggesting that gene-gene or gene-environment interactions contribute to phenotypic variability.

Indexed as

MutationAdolescentAdultAgedAged, 80 and overAge FactorsDisease ProgressionDNA Mutational AnalysisFemaleGene-Environment InteractionGenetic Predisposition to DiseaseHumansKidneyKidney Failure, ChronicMaleMiddle AgedMUC1 protein, humanMucin-1

Identifiers

PMID24509297
PMCPMC3944763
OpenAlexW2121112464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.